DDInter557 DDInter909
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Dihydroergotamine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Imatinib
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Imatinib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Dihydroergotamine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Imatinib
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Imatinib
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Meclizine
Meclizine {u} (Compound) resembles {v} (Compound) Imatinib
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Hypotension
Hypotension {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Imatinib
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Influenza like illness
Influenza like illness {u} (Side Effect) is caused by {v} (Compound) Citalopram
Citalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Imatinib
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Pleuritic pain
Pleuritic pain {u} (Side Effect) is caused by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Imatinib
Dihydroergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Imatinib (Compound)
Dihydroergotamine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Imatinib (Compound)
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Dihydroergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Imatinib (Compound)
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Imatinib
Dihydroergotamine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Meclizine (Compound) and Meclizine (Compound) resembles Imatinib (Compound)
Dihydroergotamine (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Imatinib
Dihydroergotamine (Compound) causes Influenza like illness (Side Effect) and Influenza like illness (Side Effect) is caused by Citalopram (Compound) and Citalopram may cause a minor interaction that can limit clinical effects when taken with Imatinib
Dihydroergotamine (Compound) causes Pleuritic pain (Side Effect) and Pleuritic pain (Side Effect) is caused by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Imatinib (Compound)